Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.

Self-labelled ‘disruptor’ Mark Cuban has brought on board yet another high-demand prescription drug, following a recent deal for biosimilar Humira.

A pivotal miss leaves the company more reliant on earlier-stage pipeline programs as it talks to regulators about the path forward for its lead product.

CEO of Enzene Biosciences weighs in on the impact of Medicare negotiations in the US on the biosimilars market even as a US filing is planned for a Prolia biosimilar. In the interview, he says Enzene “is not afraid or concerned” over ongoing litigation with Merck KGaA over an Erbitux biosimilar in India, adding that new modalities like ADCs are being “seriously” considered.